As we celebrate World Veterinary Day, we would like to express our heartfelt appreciation to the entire veterinary community. We at FidoCure are proud to help serve your work and your patients with our precision medicine platform. You are the front line fighter of cancer in pets and we are honored to partner in this battle against cancer to improve the quality of life for countless dogs.
I am thrilled to join you all in commemorating National DNA Day and the role that genomics, the foundation of precision medicine, play in the future of cancer treatment.
At the AACR 2023 annual meeting, Dr. Lucas Rodrigues, Head of Veterinary Research at FidoCure®, presented the results of two innovative studies which demonstrated the power of real-world data from dogs with cancer to drive drug development strategies and inform human clinical trials.
The first study, titled "High frequency of TP53 mutations in canine skin tumors recapitulates solar induced human lesions representing an important research model of spontaneous diseases," focused on the similarities between skin tumors in dogs and humans caused by sun exposure. The study found a high frequency of TP53 mutations in canine skin tumors, mirroring those seen in humans with solar-induced skin lesions. This validates the use of dogs as a valuable research model for spontaneous diseases.
Strategic partnership leveraging FidoCure’s precision medicine platform advances joint vision for providing personalized, accessible veterinary cancer care
